Form 4: Abbott Director John Stratton Acquires Stock Equivalent Units

Abbott Laboratories Director John G. Stratton acquired 313 stock equivalent units, increasing his beneficial ownership to 13,034 units.

Summary

• John G. Stratton, a Director at Abbott Laboratories (ABT), acquired 313 stock equivalent units.
• The transaction date for these units was December 31, 2025.
• Each unit was valued at $125.29 at the time of acquisition.
• These units represent director fees credited to a stock equivalent unit account under a grantor trust.
• The units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if invested in Abbott shares.
• Following this transaction, John G. Stratton beneficially owns a total of 13,034 stock equivalent units.
• The total balance includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: Slightly positive, as an insider is increasing their stake, indicating confidence, although the units are not direct shares and are part of routine compensation.

Positives

• A director increasing their beneficial ownership, even through stock equivalent units, can signal confidence in the company's future performance.
• The stock equivalent units align the director's financial interests with shareholder returns, as they earn the same return as Abbott shares.

Negatives

• The acquired units are stock equivalent units, not direct common shares, meaning they do not confer immediate voting rights or direct equity ownership.
• Payment for these units is in cash upon retirement or reaching age 65, rather than direct share distribution, which may differ from direct equity investment.

Related Party Transactions

• The acquisition of stock equivalent units by a director as compensation constitutes a related party transaction, which is standard practice for board remuneration.

Stakeholder Impact

• Shareholders may view the director's increased beneficial ownership as a positive signal of alignment with long-term company performance.

Key Dates

Keywords

Abbott Laboratories, ABT, John G. Stratton, Director, Stock Equivalent Units, Insider Transaction, Form 4, SEC Filing, Compensation